Clinical trial
VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or…
NCT00282022 · Vion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00282022 |
|---|---|
| Title | VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer |
| Official title | A Phase II Trial of Cloretazine™ (VNP40101M) for Patients With Relapsed or Refractory Small Cell Lung Cancer |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | laromustine |
| Enrollment | 87 |
| Start date | Sep 1, 2005 |
| Primary completion | May 1, 2008 |
| First posted | Jan 25, 2006 |
| Last update posted | Nov 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: